Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is compelling because its core TTR franchise remains underpenetrated and expanding, with ATTR-CM still materially underdiagnosed and the company already seeing accelerated U.S. prescription growth as diagnosis and treatment broaden. The positive thesis is reinforced by AMVUTTRA’s leadership across the full patient spectrum, nucresiran’s deeper and faster TTR knockdown, and a structurally attractive margin profile as the next-generation asset should reduce royalty and milestone outflows over time. Beyond TTR, the pipeline adds meaningful optionality through zilebesiran, which management believes could support a broad cardiovascular label, and ALN-6400, which addresses large unmet needs in bleeding disorders with infrequent dosing and encouraging early durability signals.

Alnylam Pharmaceuticals is viewed negatively because the KARDIA-3 miss leaves the core efficacy story dependent on a contested enrichment analysis built from only 41% of Cohort A, with wide confidence intervals and a meaningful risk that control-arm intensification or regression toward the full-population result will dilute the apparent benefit. The investment case is further weakened by the fact that the most compelling commercial differentiator—nighttime dipping and continuous control—was not confirmed as a prespecified endpoint in ZENITH, limiting the ability to defend premium positioning and slowing conviction in the broader RNAi platform. On top of that, AMVUTTRA economics are softening, with a ~6% U.S. net price decline modeled in 2026 and revenue cut to $4,705M, while litigation and pricing-reporting scrutiny add expense risk and could pressure gross-to-net and long-term profitability.